Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.

Protagonist Therapeutics Inc. discontinued a Phase IIb study for the experimental ulcerative colitis treatment PTG-100 following a review from an Independent Data Monitoring Committee (DMC).

Celgene is scrapping a late-stage Crohn’s disease drug it acquired in a $710 million deal three years ago following an interim data analysis.

The FDA approved Boehringer Ingelheim Pharmaceuticals’ Cyltezo, a biosimilar to Humira, in a pre-filled syringe for treating chronic inflammatory diseases.

A biosimilar version of AbbVie Inc.’s blockbuster arthritis drug Humira, produced by a joint venture of Biogen Inc. and Samsung Biologics, was approved by EU regulators.

Celgene Corp. said its oral drug to treat relapsing multiple sclerosis met the main goal in a second late-stage study.

Pfizer will begin shipping its biosimilar version of J&J’s rheumatoid arthritis drug Remicade in late November 2016 at a 15% discount to current wholesale prices.

AbbVie’s biologic therapy Humira for autoimmune diseases was the worldwide prescription-drug sales leader in 2015 for the fourth consecutive calendar term.

April 20, 2016By Mark Terry, BioSpace.com Breaking News Staff   South San Francisco-based Second Genome announced today that it had closed on a Series B investment round with $42.6 million. It was co-led by Pfizer Venture Investments and Roche Venture Fund. They were joined by new investors, Digitalis Ventures, Adveq, LifeForce Capital, MBL Venture Capital, […]

January 28, 2016 By Mark Terry, BioSpace.com Breaking News Staff   Cambridge, Mass.-based Biogen Inc. (BIIB) announced its 2015 financial and fourth-quarter reporting yesterday, citing $10.8 billion in annual revenues, an increase of 11 percent over 2014. Biogen exceeded analysts expectations, who were predicting a revenue increase of about 9 percent. Net income was $3.6 […]